Comparative study on gene set and pathway topology-based enrichment methods by Michaela Bayerlová et al.
RESEARCH ARTICLE Open Access
Comparative study on gene set and pathway
topology-based enrichment methods
Michaela Bayerlová1, Klaus Jung1, Frank Kramer1, Florian Klemm2, Annalen Bleckmann1,2 and Tim Beißbarth1*
Abstract
Background: Enrichment analysis is a popular approach to identify pathways or sets of genes which are significantly
enriched in the context of differentially expressed genes. The traditional gene set enrichment approach considers a
pathway as a simple gene list disregarding any knowledge of gene or protein interactions. In contrast, the new group
of so called pathway topology-based methods integrates the topological structure of a pathway into the analysis.
Methods: We comparatively investigated gene set and pathway topology-based enrichment approaches, considering
three gene set and four topological methods. These methods were compared in two extensive simulation studies and
on a benchmark of 36 real datasets, providing the same pathway input data for all methods.
Results: In the benchmark data analysis both types of methods showed a comparable ability to detect enriched
pathways. The first simulation study was conducted with KEGG pathways, which showed considerable gene overlaps
between each other. In this study with original KEGG pathways, none of the topology-based methods outperformed
the gene set approach. Therefore, a second simulation study was performed on non-overlapping pathways created by
unique gene IDs. Here, methods accounting for pathway topology reached higher accuracy than the gene set
methods, however their sensitivity was lower.
Conclusions: We conducted one of the first comprehensive comparative works on evaluating gene set against pathway
topology-based enrichment methods. The topological methods showed better performance in the simulation scenarios
with non-overlapping pathways, however, they were not conclusively better in the other scenarios. This suggests that
simple gene set approach might be sufficient to detect an enriched pathway under realistic circumstances. Nevertheless,
more extensive studies and further benchmark data are needed to systematically evaluate these methods and to assess
what gain and cost pathway topology information introduces into enrichment analysis. Both types of methods for
enrichment analysis require further improvements in order to deal with the problem of pathway overlaps.
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Background
Analysis of gene expression experiments typically yields
long lists of differentially expressed genes (DEGs) [1]. To
ease interpretation of such results it has been proposed
to analyse expression data in the context of biological
pathways or other biologically meaningful gene sets
instead of individual genes [2]. There are many tests,
which aim to detect pathways significantly enriched
between two experimental conditions [3–6]. These tests
were implemented into a plethora of methods that differ
in many aspects ranging from null hypothesis formulation,
through statistical framework up to pathway data encod-
ing, database support and software availability.
We were interested to evaluate different methods for
analysing gene expression data in the context of signalling
pathways, with a special focus on comparing methods
with different pathway representation strategies. There are
different approaches how to handle a pathway in enrich-
ment analysis. The traditional approach considers a path-
way as a simple gene list omitting any knowledge of the
gene and protein interactions. Methods belonging to this
category are commonly called gene set (GS) analysis
methods. Another way of integrating a pathway into
enrichment analysis takes into account its graphical struc-
ture and/or topological measures. One of the first pathway
topology-based (PT-based) methods was impact analysis
* Correspondence: Tim.Beissbarth@ams.med.uni-goettingen.de
1Department of Medical Statistics, University Medical Center Göttingen,
37099 Göttingen, Germany
Full list of author information is available at the end of the article
© 2015 Bayerlová et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bayerlová et al. BMC Bioinformatics  (2015) 16:334 
DOI 10.1186/s12859-015-0751-5
proposed by Draghici et al. [7]. Since then this has ap-
proach become very popular, resulting in a number of PT-
based algorithms being published [8–11].
Enrichment methods can be divided into two groups
based on the null hypothesis: (i) competitive methods
which are naturally linked with gene sampling for p-value
calculation and (ii) the group of self-contained methods
which is associated with subject sampling [12]. The basic
difference between these two groups is that competitive
methods compare genes in a pathway to its complement
usually represented by the rest of the genes measured in
the experiment, while self-contained methods consider
only genes within a pathway and test their association
with the phenotype. Both approaches have their limita-
tions. On the one hand, competitive methods coupled
with a gene sampling model for p-value calculation
assume independence of genes, which is known not to be
true. On the other hand, self-contained methods were crit-
icized for being too powerful and thus yielding too many
significant gene sets. Also the number of replicates in the
experiments is often too low for subject sampling [12].
Another classification of enrichment methods sepa-
rates them into over-representation analysis (ORA) and
functional class scoring (FCS) approaches [13]. ORA is
commonly referring to 2×2 table methods such as Fish-
er’s exact test, hypergeometric test and chi-squared test.
It represents exclusively the competitive approach. The
ORA methods require a strict cut-off in the list of DEGs
and therefore the results are strongly dependent on the
chosen threshold. FCS comprises methods, which first
score genes and then transform gene level scores into
pathway level scores. This group includes both com-
petitive and self-contained methods, depending on the
pathway-level transformation and significance assess-
ment of pathway level score. Most of the PT-based
methods can be classified into either ORA or FCS, how-
ever in some cases it might be difficult to draw a strict line.
From the user’s point of view there are several features
of the enrichment methods to be considered besides
classification of the methods according to methodological
and statistical framework. For instance, the implementa-
tion and availability of the software can determine how
popular a method becomes. Furthermore, several pathway
databases such as Kyoto Encyclopedia of Genes and Ge-
nomes (KEGG) [14], Reactome [15], Pathway Interaction
Database [16] or BioCarta [17] make data available for
pathway analysis. While it is rather straightforward to sup-
ply simple gene set of a pathway for GS methods, provid-
ing a pathway with topology information and integrate it
into a PT-based method can be more difficult. Therefore,
the utility of PT-based methods also depends on their sup-
port of different pathway databases.
Several studies comparing different GS analysis methods
were already published [18–20], as well as review papers
offering surveys of PT-based methods [13, 21]. However,
to our best knowledge there is no paper comparing the
GS against the PT-based approach systematically.
Therefore, the aim of our study is to evaluate GS versus
PT-based approaches using simulated gene expression data
as well as benchmark datasets. For comparability of the
methods we focused mainly on competitive ones, including
three GS tests and four PT-based methods implemented in
the R statistical computing environment (see Table 1). These
seven methods represent both ORA and FCS approaches.
To perform a fair comparison of the different methods
we faced two major challenges: First, it was necessary to
provide the same pathway data inputs for all methods,
which was in particular challenging for PT-based methods.
The integration of topological pathway data is described in
detail in the third section of the Methods. Second, to simu-
late expression data for evaluation of PT-based methods
was a comprehensive problem, which resulted in a com-
plex simulations scheme. Hence, we described Simulations
as a separate chapter.
Methods
In this chapter we present in detail 3 GS and 4 PT-based
enrichment methods and their use within this work.
Table 1 Summary of seven enrichment methods evaluated in this study
Test/Method name Pathway representation ORA/ FCS R-function/ package version Database support Null hypothesis
Wilcoxon rank sum GS FCS wilcox.test Any input Competitive
Kolmogorov-Smirnov GS FCS ks.test Any input Competitive
Fisher’s exact GS ORA fisher.test Any input Competitive
SPIA PT-based ORA-like 2.12.0. KEGG Competitive
CePa ORA PT-based ORA-like 0.5. KEGG, Reactome, NCI-Nature, BioCarta Competitive
CePa GSA PT-based FCS-like 0.5. Self-contained
PathNet PT-based unclass. 1.3.0. KEGG Competitive
Methods were classified according to the representation of a pathway into the gene set (GS) enrichment and the pathway topology-based (PT-based) methods.
Second column stratifies the methods into over-representation analysis (ORA) and functional class scoring (FCS). However, for PT-based methods this classification
is not always explicit, therefore we used ‘-like’ suffix and ‘unclass.’ for an unclassified method. Third column shows the utilized R-functions for GS methods and
versions of R-packages of PT-based methods. Next column summarizes the pathways databases which are provided within the R-packages. According to the null
hypothesis most of the methods are competitive, only the GSA variant of the CePa method is self-contained
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Further, we describe how pathway data were processed
and integrated into the methods. The last section of the
Methods introduces the analysis of benchmark data.
Gene set enrichment methods
We chose rather basic statistical tests to represent the
GS analysis approach: Wilcoxon rank sum (WRS),
Kolmogorov-Smirnov (KS) and Fisher’s exact (FE) tests.
These tests were implemented in various flavours and
extensions in multiple tools. For instance, the popular
GSEA [4] is based on KS statistic, the SAFE [6] and
CAMERA [22] tools employ the WRS test in different
fashions and the FE test is implemented in software
packages such as GOStat [5] and Onto-Express [3].
We utilized the R-functions wilcox.test, ks.test and
fisher.test to perform WRS, KS and FE analysis, respect-
ively within the R statistical language and environment
[23], version 2.15.1. All three tests are competitive gene
sets approaches, which require a list of p-values for differ-
ential expression [2]. WRS and KS are FCS methods
transforming the list of p-values into ranks. In our setting,
WRS tests whether the distribution of ranks of the genes
in a set is shifted to the left from a distribution of ranks of
the genes in corresponding complement to the gene set.
KS test compares the ranks of genes in a set to a uniform
distribution.
The FE test is based on ORA. The cut-off in the list of
differentially expressed genes (DEGs) was defined as
false discovery rate below 0.05 (FDR <0.05). FE is testing
independence of rows and columns in 2x2 contingency
table (while the margins are fixed) and p-values are
directly obtained using hypergeometric distribution.
Pathway-topology based enrichment methods
In this study we evaluated PT-based algorithms from three
R-packages: SPIA, CePa and Pathnet. Two variants of the
CePa method were implemented in the CePa R-package,
the so-called CePa ORA and CePa GSA, which we con-
sider as two distinct methods.
SPIA
Signaling pathway impact analysis (SPIA) is an enrichment
method combining two types of evidence, which are repre-
sented by two p-values [8]. The first p-value originates from
a simple ORA, which assumes that the number of DEGs in
a given pathway follows hypergeometric distribution. The
second, so-called perturbation p-value is computed in sev-
eral steps and incorporates pathway topology information.
To obtain the perturbation p-value, first, for each gene in a
pathway a perturbation factor is computed. It captures the
logarithm of the fold-change (logFC) of a gene and the sum
of perturbation factors of the direct upstream genes of a
gene normalized by the number of all downstream genes.
Each term of the sum is weighed by type of interaction be-
tween the genes: 1 and −1 for activation and inhibition, re-
spectively. This results in upstream gene influencing
perturbation factors of many downstream genes. In a sec-
ond step the perturbation accumulation at the level of each
pathway gene is calculated. It is defined as the difference
between the gene perturbation factor and its observed
logFC. Finally, the total pathway accumulated perturbation
is computed as a sum of the accumulated perturbations of
pathway’s genes. Significance is assessed in a bootstrap
procedure, resulting in a perturbation p-value. The
two p-values are then combined into a global p-value
for each pathway using Fisher’s product test.
CePa ORA and CePa GSA
CePa [24] is a weighed gene set analysis approach in
which weights are assessed by network centralities. The
CePa ORA method weighs the nodes of DEGs according
to one of 5 centrality measures and then sums them up
to the pathway level score. To obtain a p-value the null
distribution of the pathway score is generated by
permuting the DEGs on a given pathway topology. The
centrality measure options are in- and out-degree,
betweenness and in- and out-largest reach. Degree cen-
trality measures the number of nodes directly connected
to the given node, betweenness refers to the number of
information streams passing through a given node and
largest reach quantifies how far a node can send or
receive information. Along 5 centrality options CePa
also calculates an equal weight model where all weights
are set up to 1. Therefore, six p-values for each pathway
are calculated. We followed the authors’ recommenda-
tion to try every centrality option in the search for sig-
nificant pathways. Hence, the smallest out of 6 p-values
was selected to represent pathway significance.
Furthermore, the CePa method proposed a node-based
instead of a gene-based ID mapping approach. That
means, if any member of a complex or a group of genes
residing in one node is differentially expressed then the
node is considered as differentially expressed. Also nodes
representing non-gene components of a pathway such as
microRNA and small molecules are retained in the path-
way topology. However, these last two features of the CePa
algorithm were suppressed using our pathway input data
(for details see Pathway data section).
CePa GSA performs self-contained univariate gene set
analysis where node level statistics are weighted by cen-
trality measures and then transformed into pathway level
statistics. CePa GSA implements several alternatives for
node level statistics and transformation functions, how-
ever, we kept the default options: for node level scores the
absolute value of t-statistic was used and for comput-
ing pathway level statistics mean was used as default
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transformation function. Then the significance of each
pathway is assessed by permuting sample class labels.
PathNet
PathNet [11] is an enrichment method combining 2
types of evidences on gene-level in contrast to SPIA
which combines 2 types of evidences on pathway-level.
This method considers so-called direct and indirect evi-
dence. Direct evidence from expression data is repre-
sented by nominal p-values of the DEGs. Indirect
evidence of a gene is calculated from direct evidences of
its neighbours in a pooled pathway. The pooled pathway
is a big network created by merging all pathways pre-
sented in a given database. To calculate indirect evi-
dence, first, indirect evidence score of a gene is defined
as a sum of the negative log10 transformed p-values of
all its neighbours in the pooled pathway. Secondly, the
null distribution of this score is reconstructed by ran-
domizing direct evidence p-values on the pooled path-
way with a fixed topology and a corresponding indirect
evidence p-value is estimated. Finally, a p-value for each
gene is obtained by aggregating direct and indirect evi-
dence p-values using Fisher’s method. The significance
of a pathway is assessed via a hypergeometric test.
Pathway data
Real pathway data available from public sources were
used in this work. Within R various approaches to inte-
grate pathways into enrichment analyses are available
[25]. The three R-packages of PT-based methods com-
prise default pathway data of KEGG and other databases
(see Table 1) in a preprocessed and suitable format.
However, to ensure comparability of the evaluated algo-
rithms we supplied all methods with the same KEGG
pathway data.
Parsing the KEGG database
A BioPAX level 3 export of KEGG pathway database was
downloaded on March 2013 and parsed into R using the
rBiopaxParser R-package [26] (Fig. 1a). Non-metabolic
pathways were selected and transformed into interaction
graphs in which the nodes represent genes and the
directed edges represent activation or inhibition processes
between the genes.
After mapping HUGO Gene Nomenclature Commit-
tee (HGNC) gene symbol IDs on the graph nodes several
editing steps had to be taken (Fig. 1b). First, in case that
several nodes were annotated with the same gene
symbol, these nodes were merged into a node, which
shared all incoming and outgoing edges of the original
nodes. Next, protein complexes or gene families often
occupied a single node resulting in multiple symbol IDs
embedded in this node. Such a node was split into
multiple nodes and each one was assigned with a single
gene symbol. Finally, nodes representing small molecules
and other non-gene components were removed in a
fashion that the parents and children of such a node
stayed connected.
Transformation into suitable inputs
Depending on the method, suitable pathway input has to
be provided implying graphs transformations [27]. For
GS methods pathway graphs were converted into simple
A B C
Fig. 1 Pathway data input preparation. The workflow shows the three steps necessary to provide the same pathways to all methods. a Non-metabolic
KEGG pathways were parsed into R and represented as directed interaction graphs. b The graphs were edited in order to affiliate a single graph node
with a single gene ID. c The adjusted graphs were further transformed into suitable input formats for both, GS and PT-based methods
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lists of genes. However, for the PT-based methods specific
pathway topology inputs were required (Fig. 1c).
To create the SPIA pathway input, a graph of each
pathway was transformed into a list of 2 adjacency
matrices for activation and inhibition processes. Accord-
ingly, a vector of weights β was set to β = {1, −1} to
reflect activation and inhibition. For CePa a pathway
catalogue was constructed comprising a list of pathways
with the interaction IDs, and a table with columns for
the interaction IDs and for the corresponding input and
output interaction components. The pathway catalogue
also included a mapping table. However, in our pathway
data a single gene ID was always mapped onto one node.
Input for PathNet consisted of an adjacency matrix of a
pooled pathway, which was created by merging all data-
base pathways, an interaction table with pathway IDs
and a mapping table. The mapping table was required as
PathNet algorithm transforms gene IDs into numeric
objects and artificial integer IDs had to be generated.
All pathway data inputs were regenerated for the second
simulation study (see Simulations chapter). In this study
pathway graph nodes were relabelled with new synthetic
IDs to construct non-overlapping pathways with unique
components, while the topology of the pathway remained
intact.
Benchmark data
All datasets from the KEGGdzPathwaysGEO R-package
and 12 datasets from the KEGGandMetacoreDzPathways-
GEO R-packages were used as benchmark data [18, 28]. A
total of 36 publicly available disease datasets (see Table 2)
were analysed in the same fashion: First, multiple probes
per Entrez gene ID were removed by retaining the probe
with the highest average expression. Next, the genes that
could not be mapped onto any pathway were filtered out.
Differential expression analysis was performed by fitting
linear models using the empirical Bayes method as imple-
mented in the limma R-package [29] and p-values were
adjusted for multiple testing using the method of Benja-
mini & Hochberg [30]. Each of the 36 datasets was
matched with the corresponding KEGG pathway accord-
ing to its name, e.g. a dataset of colon cancer patients was
associated with the colorectal cancer pathway. Such a
pathway was then called a target pathway and its p-value
and rank in the database were further evaluated [18, 28].
Simulations
We generated synthetic expression data for two simula-
tion studies each comprising 5 simulation types. Simula-
tion types differed in the topology designs for pathway
deregulation and in a choice of the parameter whose
ranges were investigated (see Fig. 2).
The two distinct simulation studies differed in their
gene ID annotation. While in the first study real gene
HGNC symbols were used, in the second study these
symbols were replaced by unique synthetic IDs for all
nodes of all pathways in order to prevent overlapping of
the pathways.
Table 2 Summary of 36 datasets used in benchmark analysis
GEO accession Disease/Target pathway Samples Ref.
GSE781 Renal cell carcinoma 17 [36]
GSE1297 Alzheimer’s disease 16 [37]
GSE3467 Thyroid cancer 18 [38]
GSE3585 Dilated cardiomyopathy 12 [39]
GSE3678 Thyroid cancer 14 —
GSE4107 Colorectal cancer 22 [40]
GSE5281_EC Alzheimer’s disease 21 [41]
GSE5281_HIP Alzheimer’s disease 23 [41]
GSE5281_VCX Alzheimer’s disease 31 [41]
GSE6956AA Prostate cancer 10 [42]
GSE6956C Prostate cancer 16 [42]
GSE8671 Colorectal cancer 64 [43]
GSE8762 Huntington’s disease 22 [44]
GSE9348 Colorectal cancer 82 [45]
GSE9476 Acute myeloid leukemia 63 [46]
GSE14762 Renal cell carcinoma 21 [47]
GSE15471 Pancreatic cancer 70 [48]
GSE16515 Pancreatic cancer 30 [49]
GSE18842 Non-small cell lung cancer 88 [50]
GSE19188 Non-small cell lung cancer 153 [51]
GSE19728 Glioma 21 [52]
GSE20153 Parkinson’s disease 16 [53]
GSE20291 Parkinson’s disease 33 [54]
GSE21354 Glioma 17 [52]
GSE1145 Dilated cardiomyopathy 26 —
GSE14924_CD4 Acute myeloid leukemia 20 [55]
GSE14924_CD8 Acute myeloid leukemia 21 [55]
GSE16759 Alzheimer’s disease 8 [56]
GSE19420 Type II diabetes mellitus 24 [57]
GSE20164 Parkinson’s disease 11 [53]
GSE23878 Colorectal cancer 38 [58]
GSE24739_G0 Chronic myeloid leukemia 12 [59]
GSE24739_G1 Chronic myeloid leukemia 12 [59]
GSE32676 Pancreatic cancer 32 [60]
GSE4183 Colorectal cancer 23 [61]
GSE7305 Endometrial cancer 20 [62]
Total: 1127
The benchmark datasets were retrieved from KEGGandMetacoreDzPathwaysGEO
and KEGGdzPathwaysGEO R-packages. The columns of summary table represent
the accession number from GEO database, the name of target pathway, the num-
ber of samples for each dataset and the reference of original publication
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In both studies expression data were drawn from a multi-
variate normal distribution, always consisting of 10 control
and 10 treatment samples. As treatment samples we refer
to the group in which we introduced changes in the p-di-
mensional mean vector. By introducing changes in the
mean vector we controlled expression levels of the genes
reflecting fold-changes between the two groups. The genes
that had an increased expression above 0 are called affected.
In the (p × p)-dimensional covariance matrix employed for
the multivariate normal distribution, we introduced a
correlation of 0.8 between genes in the same pathway and
0.05 otherwise (see Additional file 1B). Variance in the
matrix was set to 2. The same covariance matrix was used
for the generation of both treatment and control samples.
Simulation studies
The differences between simulation study 1 and 2 ori-
ginate from their different pathway data inputs.
Study 1: original pathways with overlapping genes
When generating expression data for the original path-
way simulation study the dimension of mean vector was
set to p = 3173. This number represents the total num-
ber of unique gene symbols in our KEGG pathway
graphs. As the genes in this study can belong to multiple
pathways the covariance matrix was not positive-definite
(see Additional file 1A). We computed its close positive-
definite approximation using the sfsmisc R-package
(function posdefify).
Study 2: non-overlapping pathways with unique gene IDs
To simulate expression data in the second study the mean
vector dimension was p = 7697. This number represents
the total number of nodes in our KEGG pathway graphs.
The covariance matrix of p × p was constructed in a simi-
lar manner as in the first study, but as pathways do not
overlap the matrix was positive-definite by default.
Variable parameters
In each study we performed 5 simulation types. Within
a single simulation type one of the 4 parameters was
explored on several levels, while the other 3 parameters
were fixed at a certain level (see Fig. 2). This resulted in
17 distinct configurations of parameters. Each parameter
configuration was examined in 1000 simulation runs,
meaning that 1000 expression matrices were generated
for the given configuration.
The variable parameters are mean vector (mean), path-
way size (size), number of pathway (N) and detection call
(DC). The three levels of mean = {+/−1, +/−2, +/−6} re-
flect expression changes of the affected genes between
control and treatment groups. The size of the deregulated
pathways size = {small, medium, big} is given by the num-
ber of genes in a pathway. The number of deregulated
pathways N = {12, 23, 70} represents different proportions
out of all 116 pathways in the KEGG database. Four levels
of the detection call DC = {10 %, 30 %, 50 %, 70 %} give
the percentage of affected genes in a deregulated pathway.
The levels of these parameters were adjusted to reflect
Fig. 2 Five simulation types with 17 different parameter configurations. Simulation types comprise different combinations of a topology design
and a variable parameter. Within one type sever al levels of one parameter were explored while the levels of the other parameters were fixed.
This setting resulted in 17 distinct configurations (Conf.) of the parameters
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ranges from small to extreme effects that can be found in
real data. As the default – fixed parameter level we chose
moderate levels or the most general setting, depending on
a particular parameter. For a more detailed description of
the variable parameters see Additional file 2.
Topology designs for pathway deregulation
In order to deregulate a pathway within a stimulation we
needed to affect some of its genes. We examined 3
approaches how to reflect pathway topology to allocate
affected gene in a deregulated pathway: community,
betweenness and neighbourhood approach (Fig. 3).
Communities in a given pathway were detected by
an algorithm for greedy optimization of modularity
implemented in the igraph R-package (fastgreedy.commu-
nity function) [31]. It aims to find modules with dense con-
nection between the module nodes and spare connections
between nodes of different modules. For each pathway we
searched for a community which represented 45-55 % de-
tection call (DC). However, for some pathways several
communities had to be joined or a too big community had
to be cut to get the appropriate DC (Fig. 3b).
To select affected genes in the betweenness deregulation
design we considered the top highest scored betweenness
nodes (Fig. 3c). Betweenness of a node is defined as the
number of all shortest paths in a directed graph going
through a given node. The required number of the top
scored nodes for the given DC was assigned as affected.
In the neighbourhood deregulation approach one node
of a pathway is chosen and then all nodes within certain
distance create the neighbourhood (Fig. 3d). In the
search for the neighbourhoods representing different
ranges of DC we calculated the neighbourhoods of
several orders for each pathway nodes and chose the one
best fitting the required DC level (+/− 5 %).
Summary of a single simulation run
Within a given parameter configuration for a run, a cer-
tain number of pathways (depending on the setting) was
randomly chosen to be deregulated by assigning affected
genes. Then new expression data for this particular run
were drawn from the multivariate normal distribution.
The expression matrix was directly supplied to the
CePa ORA and CePa GSA algorithms. For the rest of
the methods linear models from the limma package
were fitted to identify differential genes with theirs
logFC, p-values and FDRs (false discovery rates). Those
were further supplied to the enrichment methods accord-
ing to the specific requirements of each method.
All 7 methods were evaluated within each simulation




We parsed 116 signalling pathways of the KEGG data-
base into R using rBiopaxParser and transformed them
into interaction graphs. These graphs comprised 7697
nodes in total, representing 3173 unique genes according
to gene symbol IDs. On average a single gene was
present in 2.4 pathways indicating the extent of pathway
overlaps. The pathways comprised from 5 up to 380
A
B C D
Fig. 3 Topology designs for pathway deregulation. a Example of a particular pathway with 30 genes. In order to deregulate this pathway on detection
call level e.g. DC = 50 % (+/− 5 %) we needed to assign 14–16 affected gene to this pathway and allocate them on the pathway graph according to 3
topology approaches. b In the community design two gene communities were selected to be affected (depicted in red). c Top scored betweenness
genes were depicted in red. d Gene neighbourhood of order 2 of the blue gene was affected (in red). The colour coding of graph edges represents
activation (green) and inhibition (red) interactions between the nodes
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genes with a median pathway size of 55.5 genes (see
Additional file 3). The median number of connected
components in a single pathway interaction graph was 2.
Simulation results
In both simulation studies seven enrichment methods
were evaluated in terms of accuracy, sensitivity and spe-
cificity. Here, sensitivity describes the proportion of
true-positive pathways detected out of all pathways
assigned as deregulated and specificity describes the pro-
portion of true-negative pathways out of all pathways
that were not deregulated (i.e. without assigned affected
genes). The accuracy is then given as the proposition of
true-positive and true-negative pathways detected by a
method out of all 116 pathways. Within one study, for
each of the 17 parameter configurations we computed
the median accuracy, sensitivity and specificity of 1000
simulation runs. As in many scenarios 12 pathways was
the maximum number of true-positives, the accuracy
measure was mainly driven by true-negatives. Hence, it
reflects the specificity measure to a bigger extent. There-
fore, we focus mainly on accuracy and sensitivity as they
provide more complementary view on the results and
the specificity results are reported in Additional file 4.
Study 1 with original pathways (Fig. 4)
With weak changes of the mean vector (mean = +/−1)
sensitivity of ranking GS methods – 0.67 for WRS
and 0.58 for KS – was the best, followed by PathNet
with a sensitivity of 0.5. All methods based on ORA
(both GS and PT-based) had 0 sensitivity, however,
within the accuracy they reached 0.9. With a higher
mean change, i.e. mean = {+/−2, +/−6}, all methods
were comparably sensitive (between 0.92 and 1),
while WRS reached the best accuracy scores of 0.56
and 0.54.
Fig. 4 Accuracy and sensitivity in the simulation study 1: original pathways with overlapping genes. Accuracy and sensitivity scores of 7 methods
under 17 parameter configurations. Each cell summarizes a median value of 1000 simulation runs and within each run 116 pathways were evaluated.
The same colour code key implies for all simulation types. Wilcoxon rank sum test (WRS), Kolmogorov-Smirnov test (KS), Fisher’s exact test (FE)
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In the case of small pathways being deregulated all
methods were less sensitive than for bigger pathways
and CePa GSA (self-contained) and WRS performed
best at this parameter level with a sensitivity of 0.92 and
0.83, respectively. However, within all methods the
accuracy was highest for small pathways (ranged
between 0.59–0.74) and decreases with larger pathways.
When exploring the effect of number of pathways
which were deregulated, all methods were most accurate
(0.58–0.66) when more than half of the database path-
ways were deregulated (N = 70) with WRS and CePa
ORA performing the best.
At low level of detection call (DC = 10 %) coupled
with betweenness topology design PT-based methods
and FE test were more sensitive (0.58–0.92) than ranking
GS methods (0.33–0.58). However, on 30 % and higher
DC levels all methods performed comparably well in the
term of sensitivity (0.83–1). At the same low level of
detection call (DC = 10 %) coupled with neighbour-
hood topology design PathNet had the highest sensi-
tivity of 0.58, followed by other PT-methods and FE
(0.42–0.5). However, in both DC simulation types
the accuracy ranged only between 0.56 and 0.31 for
DC = {50 %, 70 %}.
The specificity and accuracy over most of the param-
eter configurations were very low for all methods (Fig. 4
and Additional file 4). Thus, we conducted second simu-
lation study, in which we performed the same 5 simula-
tion types on the non-overlapping pathways with unique
gene IDs.
Study 2 with non-overlapping pathways (Fig. 5)
Similarly to the results of study 1, GS methods based
on ranking were the most sensitive (0.5) for the low level
of mean parameter (+/−1). In detecting small pathways
the best sensitivity (0.75) was reached by WRS and Path-
Net. However, the accuracy was the best for PT-based
methods for most of the levels of both size and mean
parameters. The sensitivity of all methods except CePa
GSA decreased when many pathways were deregulated
(N = 70), even to a bigger extent than in study 1. Inter-
estingly, for N = 70 FE and KS accuracy was only 0.4
and 0.44, respectively, while the other methods reached
an accuracy between 0.66 and 0.97. Both simulation
types with DC parameter coupled with neighbourhood
and betweenness topology designs showed similar
behaviour patterns. When pathways did not overlap a
DC level of 50 % was needed to achieve sensitivity
over 0.75, whereas for the study with original path-
ways all methods reached 0.75 sensitivity at a DC =
30 % level. For the low DC (DC = 10 %) PathNet’s
sensitivity was the best. In term of accuracy the PT-
methods performed the best.
Overall accuracy, sensitivity and specificity in the two
simulation studies
Distribution of accuracy, sensitivity and specificity results
over all 17 simulation configurations was visualized for
each method within the both studies (Fig. 6).
In the first simulation study with original overlapping
pathways the best accuracy was achieved by WRS and
SPIA. This was also reflected in the best specificity of
these two methods, while the CePa GSA performed as
the least specific method. However, the CePa methods
reached the best sensitivity, followed by ranking tests
WRS and KS.
In the second simulation study with non-overlapping
pathways, both overall accuracy and specificity in-
creased, especially for the PT-based methods. Within GS
methods there were prominent differences with KS
performing the worst. However, KS with WRS showed
as the most sensitive methods.
Benchmark results
Besides simulated expression data, 36 microarray data-
sets comprising together 1127 samples were used as a
benchmark to compare 7 enrichment methods. Every data-
set represents a certain disease and has been linked to a
defined target pathway from the KEGG database (see
Table 2): For instance, for the dataset comparing colon can-
cer samples with controls the target pathway is ‘Colon can-
cer pathway’. However, the target pathway is only one of
several potential true positive pathways in a given dataset.
Therefore, we evaluated neither sensitivity nor accuracy to
avoid a bias caused by false negative pathways. Instead, we
inspected p-values of the target pathways in 36 datasets
and their ranks in the whole KEGG database, expecting the
target pathways to be ranked close to the top [28].
The lowest p-values of the target pathways were
detected by CePa GSA, followed by Pathnet, CePa ORA
and WRS, all three with similar performance (Fig. 7a). In
the ranking of the target pathways the PathNet method
performed best (Fig. 7b). Figure 7c shows the proportion
of the significant to the not significant pathways
detected within the 36 datasets. The CePa GSA identi-
fied on average 67 % of all database pathways as signifi-
cantly enriched, while for the rest of the methods it was
between 1.5 % and 8.9 % of the significant pathways.
Discussion
In order to place long lists of differential genes into a con-
text of biological processes and pathways the enrichment
analysis strategy is widely used. In this work we compared
standard gene set (GS) enrichment tests with methods,
which attempt to incorporate pathway topology informa-
tion into analysis.
Comparing GS methods and pathways topology-based
(PT-based) enrichment approaches is challenging in two
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regards. First, the pathway input data have to be corre-
sponding for all methods to ensure a fair comparison.
Therefore, we parsed a BioPAX export of the KEGG
database and transformed the pathways into gene sets as
well as various interaction graph representations for the
different methods. Second, it is difficult to simulate
expression data for PT-based methods. The signal in a
pathway is mediated via multiple biological mechanisms.
Capturing a pathway deregulation in a graph and reflect-
ing this alteration in the synthetic expression data is an in-
triguing task. To our knowledge there is no coherent work
published on this topic. We made one of the first
attempts to generate expression data mirroring the
topology of the deregulated pathways. However, there
are several limitations in our simulation scheme. For
instance, multivariate approaches usually require more
complex covariance matrices for a fair and unbiased
evaluation, therefore, we have not included multivari-
ate self-contained methods.
We decided to use 3 approaches to allocate affected
genes to a pathway: gene community, betweenness and
neighbourhood. However, in a certain setting some
methods might be favoured due to their inherent algo-
rithms, e.g. both CePa methods by betweenness and
Fig. 5 Accuracy and sensitivity in the simulation study 2: non-overlapping pathways with unique gene IDs. Accuracy and sensitivity scores of 7 methods
under 17 parameter configurations. Each cell summarizes a median value of 1000 simulation runs and within each run 116 pathways were evaluated. The
same colour code key implies for all simulation types. Wilcoxon rank sum test (WRS), Kolmogorov-Smirnov test (KS), Fisher’s exact test (FE)
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PathNet by neighbourhood designs. Further, it could be
questioned how well these network measures reflect the
real perturbation signals in a pathway.
In the first simulation study we could not identify any
PT-based method as outstanding neither for any param-
eter configuration, nor for the overall accuracy measure.
The pathway input for this study was represented by ori-
ginal KEGG pathways, which exhibit considerable gene
overlap among each other. When a pathway was called
deregulated it received a certain number of genes assigned
as affected according to the detection call level. However, a
single gene was on average present in 2.4 pathways. This
resulted in a number of pathways, which were not consid-
ered as deregulated but also contained affected genes.
These pathways then showed up as false positives and con-
sequently led to a very low specificity and accuracy of all
methods in study 1. However, one could assume that these
‘accidental’ affected genes were allocated randomly in the
non-deregulated pathways, whereas in the deregulated
pathway they were placed in a topological context. There-
fore, it could be expected that the PT-based methods
would overcome the problem of these false positives, how-
ever, this seems not to be the case.
It was already demonstrated that ranking methods are
able to detect modest signals of deregulation better than
the ORA approach [20]. We further showed that GS
ranking methods were more sensitive than any of the
PT-based methods when gene expression changes were
Fig. 6 Overall sensitivity, specificity and accuracy in the simulations. Distribution of 3 measures for each method over 17000 simulation runs for
study 1 with the original pathways with overlapping genes and study 2 with non-overlapping pathways with unique gene IDs
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weak (mean = +/− 1). The CePa GSA method exhibited
a clearly different behaviour than the others, which was
expected from the single self-contained method included
in this work. Prominently different performance of this
self-contained method could be further enhance by the
fact that CePa computes for each pathway five p-values
corresponding to different centrality measures and the
authors of the method recommend to use the lowest
value. Therefore, its overall sensitivity in the first study
was higher than all the other competitive methods [12].
On the other hand, its specificity was utterly lost when a
lot of pathways were deregulated (study 1, N = 70). Simi-
larly, in the diseased benchmark datasets CePa GSA was
the best in identifying target pathways but it also identi-
fied more than half of all KEGG pathways as significant.
Depending on a disease, multiple pathways could be al-
tered. However, it could be questioned whether such a
number of pathways is realistic or it reflects lack of spe-
cificity of this method.
In the second simulation study with non-overlapping
pathways the overall specificity markedly increased,
mainly for the PT-based methods. This was also reflected
in the best accuracy for these four PT-based methods.
Interestingly, the overall specificity of KS was the low-
est among all methods and it was also always decreasing
when more genes were affected (see Additional file 4,
DC = 70 %, N = 70, size = big). That could stem from its
null hypothesis, as it actually tests whether a gene set or
its complement is significant [32]. In a setting when it
was the complement it resulted in the false positive
pathways in our simulations.
Because of the limitations of the simulations, which
can never completely capture complex biology, we
compared methods also on the real expression data. It is
not possible to judge overall accuracy on these 36
benchmark datasets but PathNet and WRS showed rea-
sonable ability to identify the target pathways. This sug-
gests that simple GS approach might be sufficient for
detecting enriched pathways.
Methodological aspects
Several aspects such as pathway data, overlaps of the
pathways, and experimental data linked with biological
pathways warrant further discussion in the frame of
enrichment analysis methodology.
Pathway data stored in the databases are never
complete, but regularly curated and updated. To process
a new database version into a topological pathway input
takes more time and effort than to create the gene sets.
Therefore, the PT-based methods are less flexible than
GS methods within the respect of pathway data. Further,
the true topology of a pathway is context-dependent and
differs in between organisms, cell types and tissues [13].
The problem of pathway overlaps has already been
pointed out by several authors, including the authors of
CePa and PathNet [11, 24] and others [28, 33]. The
PathNet method claims to account for the overlap prob-
lem by constructing the pooled pathway. From the
results of study 1 the PT-based approach does not ap-
pear to address this problem. However, this might be
caused by a limited simulation design. There were fur-
ther suggestions to overcome the problem of pathway
overlaps by testing the subtracted gene sets or the inter-
sects of gene sets [33] or by down-weighting overlapping
genes in the analysis [28]. However, these approaches
were applied only within the GS methods.
Fig. 7 Comparison of 7 methods on the benchmark data. Distributions of p-values and ranks of the target pathways in 36 datasets. Methods are
ordered according to the median p-value (a) and rank (b) from the best to the worst – lower values better performance. (c) Average percentage
of the 116 pathways detected as significant and not significant by each method
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Another issue within the frame of enrichment analyses
stems from the mapping of gene expression levels on the
pathways, which consist of membrane receptors, intracel-
lular proteins, small molecules, transcription factors and
target genes. As biological pathways represent such com-
plex multi-layer models it requires considerable effort to
simplify these models into suitable inputs for enrichment
algorithms. During this simplification proteins are often
replaced by genes. This leads to a discrepancy between ex-
perimental data (gene expression profiles) and the levels
of the pathways with which they are associated. Therefore,
interpretability of results obtained within such an approach
is limited, even if the gene expression data does approxi-
mate the proteome to a certain extent. Furthermore, if a
pathway gene set, used as prior knowledge for the
enrichment analysis, does not properly reflect the ex-
perimental data, we cannot expect that adding topo-
logical information into such a gene set would
increase the method’s performance.
A straightforward solution to address this discrepancy
would be to test enrichment of signalling pathways in
protein abundance data as they reflect the protein
character of the pathways much more closely. Another
solution might be to move from testing enrichment of
pathways to testing sets of target genes of transcription
factors, as already proposed by Naeem et al. [34].
However, this requires databases, which collect and cur-
ate this type of knowledge. The Broad Institute offers
within its Molecular Signatures Database [35] several
interesting gene set collections. For instance, the tran-
scription factor targets (C3 TFT) is a collection of sets
of genes that share a transcription factor binding site.
The chemical and genetic perturbations (C2 CGP) col-
lection represents expression signatures of perturbation
experiments. Within the analysis of gene expression
data, testing these sets might be more appropriate than
testing pathways. Therefore, a gene set does not neces-
sarily have to represent only a pathway. Furthermore, it
is easier to handle a gene set in comparison to the topo-
logical representation of a pathway. Within the PT-
based methods it should also be considered that the
pathway topology might be biased or incomplete. More-
over, a pathway in a database is usually given by a cer-
tain condition or state, while the experimental data
examined in the enrichment analysis comes from bio-
logical systems under different states, conditions or dis-
ease type. However, visualization of analysed pathways
as networks can ease the biological interpretations and
reveal further findings of interesting genes and
interactions.
Usually, new PT-based methods are evaluated on a small
number of real datasets and not in all cases their perform-
ance is compared to any other PT-based method [8–11,
24]. We offered one of the first comparative study on PT-
based and GS methods, however more comprehensive
studies and further benchmark data are needed to system-
atically evaluate these methods.
Conclusions
Enrichment analysis is a useful and popular approach to
ease interpretation of high throughput data. We com-
paratively investigated 3 gene set (GS) and 4 pathway
topology-based (PT-based) methods in extensive simula-
tion studies and on real benchmark data.
Our results are consistent with some already published
findings: As expected, the self-contained method behaved
differently than the competitive ones. The ranking
methods were more sensitive than over-representation
analysis methods when expression changes were moder-
ate. Further, we demonstrated that on original KEGG
pathways none of the PT-based methods was clearly out-
performing the GS approach, neither in simulations nor in
benchmark testing. This changed in the simulation study
with non-overlapping pathways, where the PT-based
approach exceeded simple GS tests. This suggests that fur-
ther conceptual work has to be done to deal with the
problem of pathway overlaps.
From the gene set methods Wilcoxon rank sum test
performed comparably as topological methods in most
settings, and it is much easier to use and re-implement
with different input data than PT-based approaches.
Including topology to test for enrichment of a pathway
is an interesting approach. It introduces additional infor-
mation into the analysis and allows attractive visualiza-
tions of the pathway graphs. However, it needs to be
further explored whether the additional biological in-
sights justify the increased complexity of the PT-based
enrichment analyses.
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